Prevention of bone loss by using Lactobacillus-fermented milk products in a rat model of glucocorticoid-induced secondary osteoporosis

Chul Sang Lee, Byoung Kook Kim, In Ock Lee, Na Hyun Park, Sae Hun Kim

Research output: Contribution to journalArticlepeer-review

Abstract

Secondary osteoporosis is a common side effect of glucocorticoid treatments. The anti-osteoporotic role of two fermented milk products (FMPs), produced with Lactobacillus plantarum A41 and Lactobacillus fermentum SRK414, in alleviating secondary osteoporotic symptoms induced by dexamethasone (Dex) injection in rats was investigated. The two FMPs could prevent Dex-induced bone loss in rats. The two FMPs normalised altered gene expression levels of bone metabolism-related markers (osteoprotegerin, osteocalcin, bone sialoprotein, receptor activator of nuclear factor kappa-B ligand, and tartrate-resistant acid phosphatase). Furthermore, they regulated gene expression levels of bone morphogenetic protein 2-related and cell apoptosis markers in the tibia and calcium metabolism-related markers in the ileum. Additionally, these treatments modulated faecal bacterial populations by increasing Lactobacillus colonies. FMPs fermented by L. plantarum A41 and L. fermentum SRK414 were capable of preventing glucocorticoid-induced secondary osteoporosis via regulation of intestinal microbiota and gene expression levels of bone cell apoptosis related markers.

Original languageEnglish
Article number104788
JournalInternational Dairy Journal
Volume109
DOIs
Publication statusPublished - 2020 Oct

ASJC Scopus subject areas

  • Food Science
  • Applied Microbiology and Biotechnology

Fingerprint Dive into the research topics of 'Prevention of bone loss by using Lactobacillus-fermented milk products in a rat model of glucocorticoid-induced secondary osteoporosis'. Together they form a unique fingerprint.

Cite this